Belzutifan
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 215 publications
Genome-wide CRISPR screen identifies a cytokine-enhancer circuit driving HIF-2α activation in renal cancer.
Journal: The Journal of clinical investigation
Published: March 24, 2026
HIF-2α Inhibitor Combinations Knock Back Kidney Cancer in Two Trials.
Journal: Cancer discovery
Published: March 10, 2026
Belzutifan for Advanced Pheochromocytoma or Paraganglioma.
Journal: The New England journal of medicine
Published: February 11, 2026
Belzutifan for Advanced Pheochromocytoma or Paraganglioma. Reply.
Journal: The New England journal of medicine
Published: February 11, 2026
Belzutifan for Advanced Pheochromocytoma or Paraganglioma.
Journal: The New England journal of medicine
Published: February 11, 2026
Oncometabolites and Hypoxia-Regulated Exosomes Shape HIF-Driven Macrophage Programs Across Type 2 Diabetes, Atherosclerosis, and Cancer.
Journal: International journal of molecular sciences
Published: February 07, 2026
Recurrent Macular Edema Associated With Belzutifan Therapy for Metastatic Renal Cell Carcinoma.
Journal: Journal of vitreoretinal diseases
Published: February 05, 2026
Belzutifan monotherapy and combination therapies in renal cell carcinoma: a clinical trial perspective from the ARON working group.
Journal: Expert opinion on pharmacotherapy
Published: February 04, 2026
Targeting mutant VHL-gene results in therapy response in metastatic clear cell carcinoma of rete testis.
Journal: Urology case reports
Published: January 25, 2026
Real-world outcomes of third-line systemic therapy after immune checkpoint inhibitor combinations and subsequent VEGFR-TKIs in advanced renal cell carcinoma.
Journal: Japanese journal of clinical oncology
Published: January 11, 2026
Belzutifan-induced tumor regression in sporadic hemangioblastoma: a case report and literature review.
Journal: Journal of neuro-oncology
Published: December 22, 2025
SARS-CoV-2 spike S1-mediated HIF-2α activation in retinal endothelial cells suggests a mechanism contributing to post-COVID endothelial dysfunction.
Journal: Frontiers in immunology
Published: December 18, 2025
Last Updated: 04/28/2026